Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Immune Environment in Glioblastoma (Feb 2023)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editor's notes
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Footnotes
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Erratum Free access | 10.1172/JCI120803

Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression

Heng Lin, Shuang Wei, Elaine M. Hurt, Michael D. Green, Lili Zhao, Linda Vatan, Wojciech Szeliga, Ronald Herbst, Paul W. Harms, Leslie A. Fecher, Pankaj Vats, Arul M. Chinnaiyan, Christopher D. Lao, Theodore S. Lawrence, Max Wicha, Junzo Hamanishi, Masaki Mandai, Ilona Kryczek, and Weiping Zou

Find articles by Lin, H. in: JCI | PubMed | Google Scholar

Find articles by Wei, S. in: JCI | PubMed | Google Scholar

Find articles by Hurt, E. in: JCI | PubMed | Google Scholar

Find articles by Green, M. in: JCI | PubMed | Google Scholar

Find articles by Zhao, L. in: JCI | PubMed | Google Scholar

Find articles by Vatan, L. in: JCI | PubMed | Google Scholar

Find articles by Szeliga, W. in: JCI | PubMed | Google Scholar

Find articles by Herbst, R. in: JCI | PubMed | Google Scholar

Find articles by Harms, P. in: JCI | PubMed | Google Scholar

Find articles by Fecher, L. in: JCI | PubMed | Google Scholar

Find articles by Vats, P. in: JCI | PubMed | Google Scholar

Find articles by Chinnaiyan, A. in: JCI | PubMed | Google Scholar

Find articles by Lao, C. in: JCI | PubMed | Google Scholar

Find articles by Lawrence, T. in: JCI | PubMed | Google Scholar

Find articles by Wicha, M. in: JCI | PubMed | Google Scholar

Find articles by Hamanishi, J. in: JCI | PubMed | Google Scholar

Find articles by Mandai, M. in: JCI | PubMed | Google Scholar

Find articles by Kryczek, I. in: JCI | PubMed | Google Scholar

Find articles by Zou, W. in: JCI | PubMed | Google Scholar

Published April 2, 2018 - More info

Published in Volume 128, Issue 4 on April 2, 2018
J Clin Invest. 2018;128(4):1708–1708. https://doi.org/10.1172/JCI120803.
Copyright © 2018, American Society for Clinical Investigation
Published April 2, 2018 - Version history
View PDF

Related article:

Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression
Heng Lin, … , Ilona Kryczek, Weiping Zou
Heng Lin, … , Ilona Kryczek, Weiping Zou
Research Article Immunology

Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression

  • Text
  • PDF
Abstract

Programmed death-1 ligand (PD-L1, B7-H1) and programmed cell death protein 1 (PD-1) pathway blockade is a promising therapy for treating cancer. However, the mechanistic contribution of host and tumor PD-L1 and PD-1 signaling to the therapeutic efficacy of PD-L1 and PD-1 blockade remains elusive. Here, we evaluated 3 tumor-bearing mouse models that differ in their sensitivity to PD-L1 blockade and demonstrated a loss of therapeutic efficacy of PD-L1 blockade in immunodeficient mice and in PD-L1– and PD-1–deficient mice. In contrast, neither knockout nor overexpression of PD-L1 in tumor cells had an effect on PD-L1 blockade efficacy. Human and murine studies showed high levels of functional PD-L1 expression in dendritic cells and macrophages in the tumor microenvironments and draining lymph nodes. Additionally, expression of PD-L1 on dendritic cells and macrophages in ovarian cancer and melanoma patients correlated with the efficacy of treatment with either anti–PD-1 alone or in combination with anti–CTLA-4. Thus, PD-L1–expressing dendritic cells and macrophages may mechanistically shape and therapeutically predict clinical efficacy of PD-L1/PD-1 blockade.

Authors

Heng Lin, Shuang Wei, Elaine M. Hurt, Michael D. Green, Lili Zhao, Linda Vatan, Wojciech Szeliga, Ronald Herbst, Paul W. Harms, Leslie A. Fecher, Pankaj Vats, Arul M. Chinnaiyan, Christopher D. Lao, Theodore S. Lawrence, Max Wicha, Junzo Hamanishi, Masaki Mandai, Ilona Kryczek, Weiping Zou

×

Original citation: J Clin Invest. 2018;128(2):805–815. https://doi.org/10.1172/JCI96113

Citation for this erratum: J Clin Invest. 2018;128(4):1708. https://doi.org/10.1172/JCI120803

During the preparation of this manuscript, errors were introduced into the first sentences of the Abstract and Introduction as well as the labels for Figures 2 and 3. The corrected sentences and labels are below.

Abstract, first sentence:

Programmed death–ligand 1 (PD-L1, B7-H1) and programmed cell death protein 1 (PD-1) pathway blockade is a promising therapy for treating cancer.

Introduction, first sentence:

Therapeutic blockade of programmed death–ligand 1 (PD-L1, B7-H1) or programmed cell death protein 1 (PD-1) with mAbs leads to durable tumor control in a minority of patients across many cancer histologies (1, 2).

Figure 2, D, E, F and I:

The mouse genotype should be PD-1–/–.

Figure 2, G–I:

The dotted lines should be labeled Anti–PD-1.

Figure 3, F and G:

The labels for the x axes should be ID8 TDLN.

The errors have been corrected in the HTML and PDF versions of the manuscript.

The JCI regrets the errors.

Footnotes

See the related article at Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression.

Version history
  • Version 1 (April 2, 2018): Print issue publication

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Footnotes
  • Version history
Advertisement
Advertisement

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts